✦ LIBER ✦

Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides

✍ Scribed by Tjoa, B.A.; Erickson, S.J.; Bowes, V.A.; Ragde, H.; Kenny, G.M.; Cobb, O.E.; Ireton, R.C.; Troychak, M.J.; Boynton, A.L.; Murphy, G.P.

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 211 KB
Volume: 32
Category: Article
ISSN: 0270-4137
DOI: 10.1002/(sici)1097-0045(19970901)32:4<272::aid-pros7>3.0.co;2-l

No coin nor oath required. For personal study only.

✦ Synopsis

BACKGROUND.

We recently conducted a phase I clinical trial administering autologous dendritic cells pulsed with prostate-specific membrane antigen (PSMA) peptides to advanced prostate cancer patients. Participants were divided into 5 groups receiving 4 or 5 infusions of peptides alone (PSM-P1 or -P2; groups 1 and 2, respectively), autologous DC (group 3), or DC pulsed with PSM-P1 or -P2 (groups 4 and 5, respectively). Seven partial responders were observed. Follow-up evaluation of these responders is presented in this report. METHODS. Clinical monitoring for hematological studies and prostate markers was conducted up to 370 days from the start of the phase I study. Data collected include: lymphocyte, hematocrit, alkaline phosphatase, prostate-specific antigen (PSA), free PSA, and PSMA levels. RESULTS. Groups 4 and 5 (patients infused with DC pulsed with PSM-P1 or -P2) represented 5/7 responders. The length of response was between 100 days (1 patient) to 200 days or above (6 patients). Four patients still remained responsive at the end of the period of observation. CONCLUSIONS. The responses observed in this phase I clinical trial are significant and of long duration. Most of the responders were in treatment groups infused with DC pulsed with PSM-P1 or -P2, suggesting the requirement of both components for effective immunotherapy.

📜 SIMILAR VOLUMES

Higher-dose and less frequent dendritic

Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients

✍ Murphy, G.P.; Tjoa, B.A.; Simmons, S.J.; Rogers, M.K.; Kenny, G.M.; Jarisch, J. 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB 👁 2 views

## BACKGROUND. Infusion of dendritic cells (DCs) pulsed with PSMA peptides was considered possible in hormone-refractory metastatic prostate cancer patients both with or without prior treatment with a greater number of DCs and for lesser infusions than previously administered. METHODS. DCs + PSMA p

Evaluation of phase I/II clinical trials

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

✍ Tjoa, B.A.; Simmons, S.J.; Bowes, V.A.; Ragde, H.; Rogers, M.; Elgamal, A.; Kenn 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB 👁 2 views

## Background: A phase i trial involving patients with advanced prostate cancer was conducted to assess the safe administration of dendritic cells (dc) and hla-a0201-specific prostate-specific membrane antigen (psma) peptides (psm-p1 or -p2). thirty-three of the phase i participants were subsequent

Use of artificial neural networks in eva

Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patients

✍ Murphy, G.P.; Snow, P.; Simmons, S.J.; Tjoa, B.A.; Rogers, M.K.; Brandt, J.; Hea 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 138 KB 👁 2 views

## BACKGROUND. Our purpose was to compare the importance of over 22 measurements used in evaluating the clinical responses of patients with metastatic or locally recurrent prostate cancer, treated by dendritic cell (DC) infusions with prostate-specific membrane antigen (PSMA) peptides. METHODS. Art

Report of immune monitoring of prostate

Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)

✍ Salgaller, Michael L.; Lodge, Patricia A.; McLean, Joanne G.; Tjoa, Ben A.; Loft 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 336 KB 👁 2 views

## BACKGROUND. In this paper we describe our program for the immune monitoring of phase II participants given dendritic cell (DC)/prostate-specific membrane antigen (PSMA)-based immunotherapy, and we also present some initial findings. METHODS. Phase II subjects received six administrations of aut

Infusion of dendritic cells pulsed with

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

✍ Murphy, G.P.; Tjoa, B.A.; Simmons, S.J.; Jarisch, J.; Bowes, V.A.; Ragde, H.; Ro 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB 👁 2 views

## Background: A phase ii trial was conducted to assess the efficacy of infusions of dendritic cells (dc) and two hla-a2-specific psma peptides (psm-p1 and -p2). this report describes thirty three subjects with hormone-refractory metastatic prostate cancer without prior vaccine therapy history who